Company news
Korro Bio, Inc. news in 2025
Korro Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
November 12, 2025
Korro to Participate in Upcoming Investor and Scientific Conferences
September 2, 2025
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 12, 2025
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
July 21, 2025
Korro to Participate in Upcoming Investor Conferences
May 14, 2025
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
April 1, 2025
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
March 18, 2025
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
March 14, 2025
Korro to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update
January 12, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025